Results 51 to 60 of about 1,145 (113)

Nanotechnology-Driven Strategy Against SARS-CoV-2: Pluronic F127-Based Nanomicelles with or Without Atazanavir Reduce Viral Replication in Calu-3 Cells. [PDF]

Viruses
Ricci-Junior E, Rosa AS, do Nascimento T, Santos-Oliveira R, da Silva MAN, Barreto-Vieira DF, Batista LT, da Conceição GB, Quintão TAN, Ferreira VNS, Miranda MD.   +10 more
europepmc   +1 more source

Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors. [PDF]

Viruses
Makgoo L, Mosebi S, Mbita Z.
europepmc   +1 more source

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. [PDF]

Clin Infect Dis, 2023
Waalewijn H, Szubert AJ, Wasmann RE, Wiesner L, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Monkiewicz LN, Griffiths AL, Bamford A, Doerholt K, Denti P, Burger DM, Gibb DM, McIlleron HM, Colbers A, Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens (CHAPAS-4) Trial Team.   +20 more
europepmc   +1 more source

Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling. [PDF]

Pharmaceutics
Tracey H, Bate ST, Ford S, Patel P, Bloomer J, Patel A, Taskar KS.   +6 more
europepmc   +1 more source

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. [PDF]

Clin Pharmacol Ther
Dong J, Sharma P, Emara R, Cheung D, Tang W, Zhou D, Boulton DW, Någård M, Park MS.   +8 more
europepmc   +1 more source

Bioequivalence Study Recommendation for Atazanavir Sulfate Capsules by US FDA and a Contrary View

Journal of Aquaculture Research & Development, 2012
openaire   +1 more source

Detection of active pharmaceutical ingredients in surface water polluted by an informal settlement. [PDF]

Environ Monit Assess
Maraj K, Nicklin E, Edmonds-Smith C, Winter K.   +3 more
europepmc   +1 more source

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study. [PDF]

AIDS Res Ther, 2023
Srichatrapimuk S, Wongsa A, Sungkanuparph S, Kiertiburanakul S, Tassaneetrithep B, Phuphuakrat A.   +5 more
europepmc   +1 more source

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study. [PDF]

Clin Pharmacol Ther
De Nicolò A, Palermiti A, Mugerwa H, Nakabuye S, Namusanje J, Kobusingye J, Odoch D, Lamorde M, Kengo A, Denti P, Gausi K, Maartens G, McIlleron H, Wiesner L, Khoo S, Waitt C, D'Avolio A.   +16 more
europepmc   +1 more source

Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways. [PDF]

J Clin Pharmacol
Arora P, Liu H, Ling J, Hindman JT, Marathe DD.   +4 more
europepmc   +1 more source